Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683266 · ClinicalTrials.gov registry record · Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 549
- Enrollment target
- 20
- Study locations
NCT01683266: Completed Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Sanofi.
NCT01683266 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by Sanofi. The registered enrollment target is 549 participants, above the 167-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (229% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01683266, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 549 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: * To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants with type 1 diabetes mellitus Secondary Objective: * To compare HOE901-U300 and Lantus when given in the morning or in the evening in terms of: * Change of HbA1c from baseline to endpoint (scheduled Month 6) * Change from baseline to endpoint (Month 6) in fasting plasma glucose (FPG), plasma glucose prior to injection of study drug, plasma glucose at 03:00 hours, mean plasma glucose (8-point profiles), glucose variability, treatment satisfaction and health related quality of life in participants with Type 1 Diabetes Mellitus (T1DM) * Reaching target HbA1c values and controlled plasma glucose (all and reaching target without hypoglycemia) * Frequency of occurrence and diurnal distribution of hypoglycemia by category of hypoglycemia (symptomatic, asymptomatic, nocturnal, severe, probable and relative) * Safety and tolerability of HOE901-U300 including development of anti-insulin antibody (AIAs) during the 12-month study period
Conditions Studied
Interventions
- DRUG HOE901-U300 (Insulin glargine new formulation)
- DRUG Lantus (Insulin glargine)
Study Locations (20)
California
- Investigational Site Number 840430 - Bell Gardens
- Investigational Site Number 840131 - Escondido
- Investigational Site Number 840140 - Fresno
- Investigational Site Number 840107 - Greenbrae
- Investigational Site Number 840149 - Huntington Beach
- Investigational Site Number 840120 - La Jolla
- Investigational Site Number 840123 - La Mesa
- Investigational Site Number 840159 - La Mesa
- Investigational Site Number 840114 - Long Beach
- Investigational Site Number 840189 - Mission Hills
- Investigational Site Number 840105 - Temecula
- Investigational Site Number 840155 - Tustin
- Investigational Site Number 840115 - Walnut Creek
Colorado
- Investigational Site Number 840160 - Denver
- Investigational Site Number 840188 - Denver
Florida
- Investigational Site Number 840113 - Bradenton
- Investigational Site Number 840102 - Hialeah
Arizona
- Investigational Site Number 840156 - Chandler
Arkansas
- Investigational Site Number 840177 - Little Rock
Connecticut
- Investigational Site Number 840196 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 549 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
What the finished NCT01683266 record still lists
NCT01683266 is an interventional study that assigns participants to a tested intervention. The registered 549 participants enrollment target is mid-sized for trials with a published cap, above the 167-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (229% higher).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which HOE901-U300 (Insulin glargine new formulation) is the first listed.
NCT01683266 names 20 study sites across 6 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT01683266 about?
NCT01683266 is a clinical study titled "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus". Primary Objective: * To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants with type 1 diabetes mellitus Secondary Objective: * To compare HOE90...
What is the current status of trial NCT01683266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 549 participants. The study started on 2012-09. Estimated completion is 2014-03.
What conditions does trial NCT01683266 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT01683266?
The interventions under investigation include: HOE901-U300 (Insulin glargine new formulation) (DRUG), Lantus (Insulin glargine) (DRUG).
Who is sponsoring clinical trial NCT01683266?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01683266 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01683266's enrollment target sits among peer trials
549 7th of 112 higher than 106 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RECRUITING · Phase 3
-
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
-
Efficacy of Islet After Kidney Transplantation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia